S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company

Axsome Therapeutics Stock Price, News & Analysis (NASDAQ:AXSM)

$68.59
+1.16 (+1.72%)
(As of 12/5/2023 ET)
Compare
Today's Range
$67.16
$69.31
50-Day Range
$57.42
$73.06
52-Week Range
$53.71
$91.29
Volume
386,359 shs
Average Volume
827,326 shs
Market Capitalization
$3.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$105.50

Axsome Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
53.8% Upside
$105.50 Price Target
Short Interest
Bearish
16.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.50mentions of Axsome Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$828,293 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.06) to ($3.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

296th out of 948 stocks

Pharmaceutical Preparations Industry

115th out of 421 stocks


AXSM stock logo

About Axsome Therapeutics Stock (NASDAQ:AXSM)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Stock Price History

AXSM Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Q3 2023 Axsome Therapeutics Inc Earnings Call
Axsome Update: Buy At Dips And Hold Forever
Truist Financial Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
502
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$105.50
High Stock Price Target
$180.00
Low Stock Price Target
$81.00
Potential Upside/Downside
+53.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-187,130,000.00
Pretax Margin
-89.75%

Debt

Sales & Book Value

Annual Sales
$50.04 million
Book Value
$2.52 per share

Miscellaneous

Free Float
35,727,000
Market Cap
$3.25 billion
Optionable
Optionable
Beta
1.94
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 55)
    Founder, Chairman, CEO & President
    Comp: $1.32M
  • Mr. Nick Pizzie CPAMr. Nick Pizzie CPA (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $732.94k
  • Mr. Mark L. Jacobson (Age 40)
    COO & Secretary
    Comp: $784.66k
  • Mr. Hunter Murdock Esq. (Age 43)
    General Counsel & Secretary
    Comp: $735.39k
  • Dr. Amanda Jones Pharm.D. (Age 40)
    Senior Vice President of Clinical Development
  • Ms. Lori Englebert M.B.A. (Age 45)
    Executive Vice President of Commercial & Business Development
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Finance














AXSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price target for 2024?

9 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' stock. Their AXSM share price targets range from $81.00 to $180.00. On average, they anticipate the company's stock price to reach $105.50 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2023?

Axsome Therapeutics' stock was trading at $77.13 at the beginning of 2023. Since then, AXSM stock has decreased by 11.1% and is now trading at $68.59.
View the best growth stocks for 2023 here
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its earnings results on Monday, November, 6th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $0.08. The company earned $57.79 million during the quarter, compared to the consensus estimate of $54.88 million. Axsome Therapeutics had a negative net margin of 90.33% and a negative trailing twelve-month return on equity of 88.79%. During the same period in the previous year, the business posted ($1.03) EPS.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (9.49%), FMR LLC (3.93%), Alethea Capital Management LLC (1.60%), Northern Trust Corp (0.74%), Eventide Asset Management LLC (0.73%) and Adage Capital Partners GP L.L.C. (0.69%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AXSM) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -